Drug · DIN 02440601
REVLIMID
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 5, 2025; first marketed September 28, 2015.
- Drug Identification Number (DIN)
- 02440601
- Company (DIN owner)
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lenalidomide L04AX04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LENALIDOMIDE | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 9, 2024: NOC 32672New Drug Submission (NDS) · Administrative: Change in Product Ownership
- May 4, 2015: NOC 16861Supplement to a New Drug Submission (SNDS) · New strength - 20 mg
Other DINs named REVLIMID
- DIN 02304899 · Marketed
- DIN 02304902 · Marketed
- DIN 02317699 · Marketed
- DIN 02317710 · Marketed
- DIN 02459418 · Marketed